consider
recent
interest
caus
mechan
exacerb
copd
copd
exacerb
import
caus
consider
morbid
mortal
found
copd
copd
exacerb
increas
increas
sever
copd
patient
prone
frequent
exacerb
import
caus
hospit
admiss
readmiss
frequent
exacerb
may
consider
impact
qualiti
life
activ
daili
live
copd
exacerb
also
associ
consider
physiolog
deterior
increas
airway
inflammatori
chang
caus
varieti
factor
virus
bacteria
possibl
common
pollut
fig
copd
exacerb
common
winter
month
may
import
interact
cold
temperatur
exacerb
caus
virus
pollut
earlier
descript
copd
exacerb
concentr
mainli
studi
hospit
admiss
though
copd
exacerb
treat
commun
associ
hospit
admiss
cohort
moder
sever
copd
patient
follow
east
london
uk
east
london
copd
studi
daili
diari
card
peak
flow
read
patient
ask
report
exacerb
soon
possibl
symptomat
onset
diagnosi
copd
exacerb
base
criteria
modifi
describ
anthonisen
colleagu
requir
two
symptom
diagnosi
one
must
major
symptom
increas
dyspnea
sputum
volum
sputum
purul
minor
exacerb
symptom
includ
cough
wheez
sore
throat
nasal
discharg
fever
tabl
studi
found
exacerb
unreport
research
team
despit
consider
encourag
provid
diagnos
diari
card
though
differ
major
symptom
physiolog
paramet
report
unreport
exacerb
patient
copd
accustom
frequent
symptom
chang
thu
may
tend
underreport
exacerb
physician
patient
high
level
anxieti
depress
may
accept
situat
tendenc
patient
underreport
exacerb
may
explain
higher
total
rate
exacerb
per
patient
per
year
higher
previous
report
anthonisen
cowork
per
patient
per
year
howev
latter
studi
exacerb
unreport
diagnos
patient
recal
symptom
use
median
number
exacerb
cutoff
point
copd
patient
east
london
studi
classifi
frequent
infrequ
exacerb
qualiti
life
score
measur
use
valid
diseasespecif
scale
st
georg
respiratori
questionnair
sgrq
significantli
wors
three
compon
score
symptom
activ
impact
frequent
compar
infrequ
exacerb
suggest
exacerb
frequenc
import
determin
health
statu
copd
thu
one
import
outcom
measur
copd
factor
predict
frequent
exacerb
includ
daili
cough
sputum
frequent
exacerb
previou
year
previou
studi
acut
infect
exacerb
chronic
bronchiti
found
one
factor
predict
exacerb
also
number
previou
year
though
studi
limit
exacerb
present
purul
sputum
physiolog
data
avail
studi
prospect
analysi
exacerb
daili
monitor
perform
deterior
symptom
though
signific
peak
flow
chang
fall
peak
flow
fev
exacerb
gener
small
use
predict
exacerb
larger
fall
peak
flow
associ
symptom
dyspnea
presenc
cold
relat
longer
recoveri
time
exacerb
symptom
dyspnea
common
cold
sore
throat
cough
increas
significantli
prodrom
phase
suggest
respiratori
virus
may
earli
effect
exacerb
median
time
recoveri
peak
flow
day
day
symptom
day
peak
flow
return
normal
exacerb
day
exacerb
return
baselin
lung
function
recoveri
longer
presenc
increas
dyspnea
symptom
common
cold
exacerb
chang
observ
lung
function
exacerb
smaller
observ
asthmat
exacerb
though
averag
durat
asthmat
exacerb
longer
day
reason
incomplet
recoveri
symptom
lung
function
clear
may
involv
inadequ
treatment
persist
caus
agent
incomplet
physiolog
recoveri
exacerb
could
contribut
declin
lung
function
time
patient
copd
howev
date
evid
patient
incomplet
recoveri
exacerb
greater
declin
lung
function
studi
natur
histori
copd
exacerb
requir
associ
symptom
increas
dyspnea
common
cold
exacerb
prolong
recoveri
suggest
viral
infect
may
lead
prolong
exacerb
cold
associ
longer
exacerb
copd
patient
develop
cold
may
prone
sever
exacerb
consid
therapi
earli
onset
symptom
although
assum
exacerb
associ
increas
airway
inflamm
littl
inform
avail
natur
inflammatori
marker
especi
studi
close
exacerb
perform
bronchial
biopsi
exacerb
difficult
patient
moder
sever
copd
relat
airway
inflammatori
chang
symptom
physiolog
chang
exacerb
copd
also
import
factor
consid
one
studi
biopsi
perform
exacerb
patient
chronic
bronchiti
increas
airway
eosinophilia
found
though
patient
studi
mild
copd
exacerb
modest
increas
observ
neutrophil
tlymphocyt
tumor
necrosi
factora
tnfa
posit
cell
chang
cell
macrophag
mast
cell
howev
techniqu
sputum
induct
allow
studi
patient
exacerb
shown
safe
welltoler
techniqu
copd
patient
level
inflammatori
cytokin
shown
elev
induc
sputum
copd
patient
stabl
though
chang
exacerb
previous
studi
prospect
follow
cohort
patient
east
london
copd
studi
inflammatori
marker
induc
sputum
relat
symptom
physiolog
paramet
baselin
exacerb
relat
exacerb
frequenc
sputum
cytokin
increas
sputum
found
patient
baselin
stabl
frequent
exacerb
compar
infrequ
exacerb
fig
although
relat
cytokin
baselin
lung
function
sputum
cell
count
increas
baselin
patient
frequent
exacerb
suggest
increas
cytokin
product
come
bronchial
epithelium
copd
discuss
exacerb
trigger
viral
infect
especi
rhinoviru
caus
common
cold
rhinoviru
shown
increas
cytokin
product
epitheli
cell
line
thu
repeat
viral
infect
may
lead
upregul
cytokin
airway
express
exacerb
increas
found
induc
sputum
interleukin
il
level
level
higher
exacerb
associ
symptom
common
cold
fig
experiment
rhinoviru
infect
shown
increas
sputum
normal
subject
asthmat
howev
rise
cell
count
variabl
exacerb
reach
statist
signific
suggest
mark
heterogen
degre
inflammatori
respons
exacerb
exacerb
level
relat
sputum
neutrophil
total
cell
count
indic
neutrophil
recruit
major
sourc
airway
exacerb
lower
airway
shown
increas
experiment
rhinoviru
infect
normal
asthmat
patient
studi
other
howev
copd
patient
alreadi
upregul
airway
level
stabl
due
high
sputum
neutrophil
load
increas
would
unlik
copd
exacerb
associ
less
pronounc
airway
inflammatori
respons
asthmat
exacerb
may
explain
rel
reduc
respons
steroid
seen
exacerb
copd
patient
rel
asthma
studi
perform
bhowmik
colleagu
increas
seen
eosinophil
count
exacerb
even
though
patient
studi
sampl
earli
exacerb
onset
symptom
compar
studi
saetta
colleagu
patient
mild
copd
patient
sever
irrevers
airflow
obstruct
fev
predict
thu
possibl
inflammatori
respons
exacerb
differ
natur
patient
moder
sever
copd
patient
milder
copd
patient
follow
daili
diari
card
studi
bhowmik
colleagu
thu
inflammatori
respons
could
relat
exacerb
recoveri
relat
degre
inflammatori
cell
respons
exacerb
durat
symptom
lung
function
chang
induc
sputum
marker
taken
week
exacerb
show
relat
exacerb
chang
thu
level
induc
sputum
marker
exacerb
predict
subsequ
cours
exacerb
use
predict
exacerb
sever
copd
exacerb
associ
number
etiolog
factor
includ
infect
pollut
episod
tabl
copd
exacerb
frequent
trigger
upper
respiratori
tract
infect
common
winter
month
respiratori
viral
infect
commun
patient
may
also
prone
exacerb
winter
month
lung
function
copd
patient
show
small
signific
fall
reduct
outdoor
temperatur
winter
month
copd
patient
found
increas
hospit
admiss
suggest
increas
exacerb
increas
environment
pollut
occur
decemb
pollut
episod
uk
copd
mortal
increas
togeth
increas
hospit
admiss
elderli
copd
patient
howev
common
pollut
especi
oxid
nitrogen
particul
may
interact
viral
infect
precipit
exacerb
rather
act
alon
virus
especi
rhinoviru
caus
common
cold
detect
polymeras
chain
reaction
larg
number
exacerb
rhinoviru
hitherto
consid
much
signific
exacerb
copd
studi
chronic
bronchit
year
stott
colleagu
found
rhinoviru
exacerb
chronic
bronchiti
detail
studi
chronic
bronchit
exacerb
year
gump
et
al
found
exacerb
could
attribut
rhinovirus
recent
studi
episod
copd
exacerb
use
serolog
method
nasal
sampl
viral
cultur
littl
evid
found
rhinoviru
etiolog
copd
exacerb
two
recent
studi
show
least
onethird
copd
exacerb
associ
viral
infect
major
due
rhinoviru
viral
exacerb
associ
symptomat
cold
prolong
recoveri
howev
seemung
colleagu
show
rhinoviru
recov
induc
sputum
frequent
nasal
aspir
exacerb
suggest
wildtyp
rhinoviru
infect
lower
airway
contribut
inflammatori
chang
exacerb
also
found
exacerb
associ
presenc
rhinoviru
induc
sputum
larger
increas
airway
level
suggest
virus
increas
sever
airway
inflamm
exacerb
find
agreement
data
respiratori
virus
produc
longer
sever
exacerb
major
impact
health
care
util
virus
may
trigger
copd
exacerb
though
coronaviru
associ
small
proport
asthmat
exacerb
unlik
play
major
role
copd
bacteri
colon
airway
bacteri
colon
found
approxim
copd
patient
colon
shown
relat
degre
airflow
obstruct
current
cigarett
smoke
statu
although
bacteria
haemophilu
influenza
streptococcu
pneumonia
associ
copd
exacerb
studi
shown
increas
bacteri
count
exacerb
other
confirm
find
soler
colleagu
show
presenc
potenti
pathogen
organ
bronchoalveolar
lavag
copd
patient
bronchoscopi
associ
greater
degre
neutrophilia
higher
tnfa
level
hill
colleagu
larger
studi
show
airway
bacteri
load
relat
inflammatori
marker
also
found
bacteri
speci
relat
degre
inflamm
pseudomona
aeruginosa
colon
show
greater
myeloperoxidas
activ
indirect
measur
neutrophil
activ
thu
bacteri
colon
copd
may
import
determin
airway
inflamm
thu
longterm
studi
requir
whether
bacteri
colon
predispos
declin
lung
function
characterist
copd
evid
patient
frequent
exacerb
increas
sputum
bacteri
colon
explain
higher
cytokin
level
observ
frequent
exacerb
patient
group
howev
also
possibl
may
interact
viral
bacteri
infect
copd
exacerb
organ
chlamydia
pneumonia
associ
asthmat
exacerb
may
also
play
role
copd
exacerb
rel
littl
inform
avail
patholog
chang
airway
copd
exacerb
patient
moder
sever
copd
mechan
perform
respiratori
muscl
reduc
airflow
obstruct
lead
hyperinfl
respiratori
muscl
act
mechan
disadvantag
gener
reduc
inspiratori
pressur
load
respiratori
muscl
also
increas
patient
airflow
obstruct
presenc
intrins
posit
endexpiratori
pressur
peep
exacerb
copd
increas
airflow
obstruct
increas
load
respiratori
muscl
increas
work
breath
precipit
respiratori
failur
sever
case
minut
ventil
may
normal
respiratori
pattern
irregular
increas
frequenc
decreas
tidal
volum
result
hypercapnia
acidosi
reduc
inspiratori
muscl
function
contribut
deterior
respiratori
failur
hypoxemia
copd
usual
occur
due
combin
ventilationperfus
mismatch
hypoventil
although
arterioven
shunt
also
contribut
acut
settingthi
caus
increas
pulmonari
arteri
pressur
lead
salt
water
retent
develop
edema
degre
ventil
perfus
abnorm
increas
acut
exacerb
resolv
follow
week
acidosi
import
prognost
factor
surviv
respiratori
failur
copd
exacerb
thu
earli
correct
acidosi
essenti
goal
therapi
anticholinerg
agent
inhal
bronchodil
frequent
use
treatment
acut
exacerb
copd
patient
stabl
copd
symptomat
benefit
obtain
bronchodil
therapi
copd
even
without
signific
chang
spirometri
probabl
due
reduct
dynam
hyperinfl
characterist
copd
henc
lead
decreas
sensat
dyspnea
especi
exert
stabl
copd
greater
bronchodilat
demonstr
anticholinerg
agent
b
agonist
may
due
excess
cholinerg
neuron
bronchoconstrictor
tone
howev
studi
investig
bronchodil
respons
acut
exacerb
copd
shown
differ
agent
use
signific
addit
effect
combin
therapi
even
though
combin
anticholinerg
bronchodil
benefit
stabl
state
differ
effect
acut
stabl
state
may
due
fact
larger
dose
drug
deliv
acut
set
produc
maxim
bronchodilat
wherea
smaller
dose
administ
stabl
condit
may
submaxim
effect
methylxanthin
theophyllin
sometim
use
manag
acut
exacerb
copd
evid
theophyllin
use
copd
though
main
limit
factor
frequenc
toxic
sideeffect
therapeut
action
theophyllin
thought
due
inhibit
phosphodiesteras
break
cyclic
amp
intracellular
messeng
thu
facilit
bronchodilat
howev
studi
intraven
aminophyllin
therapi
acut
exacerb
copd
shown
signific
benefici
effect
convent
therapi
report
benefici
effect
methylxanthin
upon
diaphragmat
cardiac
function
though
mechan
requir
studi
patient
copd
exacerb
patient
stabl
copd
show
spirometr
respons
oral
corticosteroid
unlik
situat
asthma
steroid
littl
effect
airway
inflammatori
marker
patient
copd
although
corticosteroid
tradit
use
manag
acut
exacerb
copd
recent
evid
benefici
role
acut
situat
number
earli
studi
investig
effect
corticosteroid
therapi
copd
exacerb
earli
control
trial
patient
copd
exacerb
acut
respiratori
failur
albert
cowork
found
larger
improv
preand
postbronchodil
fev
patient
treat
first
day
hospit
admiss
intraven
methylprednislon
treat
placebo
anoth
trial
found
singl
dose
methylprednisolon
given
within
minut
arriv
accid
emerg
depart
produc
improv
hour
spirometri
also
effect
hospit
admiss
though
anoth
studi
reduc
readmiss
retrospect
studi
patient
treat
steroid
exacerb
compar
treat
show
steroid
group
reduc
chanc
relaps
therapi
thompson
colleagu
gave
cours
prednisolon
placebo
random
manner
outpati
present
acut
exacerb
copd
unlik
previou
studi
patient
either
recruit
outpati
group
preenrol
selfreport
exacerb
studi
team
studi
patient
exacerb
associ
acidosi
pneumonia
exclud
exacerb
moder
sever
gener
includ
patient
steroidtr
group
show
rapid
improv
p
alveolararteri
oxygen
gradient
fev
peak
expiratori
flow
rate
trend
toward
rapid
improv
dyspnea
recent
cohort
studi
seemung
colleagu
effect
therapi
prednisolon
copd
exacerb
diagnos
treat
commun
studi
exacerb
treat
steroid
sever
associ
larger
fall
peak
flow
rate
treat
exacerb
also
longer
recoveri
time
baselin
symptom
peak
flow
rate
howev
rate
peak
flow
rate
recoveri
faster
prednisolonetr
group
though
rate
symptom
score
recoveri
interest
find
studi
steroid
significantli
prolong
median
time
day
onset
initi
exacerb
next
exacerb
day
group
treat
prednisolon
day
patient
treat
prednisolon
contrast
antibiot
therapi
effect
time
next
exacerb
short
cours
oral
steroid
therapi
exacerb
prolong
time
next
exacerb
could
import
way
reduc
exacerb
frequenc
copd
patient
import
determin
health
statu
davi
colleagu
studi
patient
admit
hospit
copd
exacerb
random
prednisolon
placebo
prednisolon
group
fev
rose
faster
day
plateau
observ
steroidtr
group
chang
prebronchodil
postbronchodil
fev
similar
suggest
effect
bronchomotor
tone
involv
faster
resolut
airway
inflammatori
chang
airway
wall
edema
exacerb
length
hospit
stay
analysi
show
patient
treat
prednisolon
significantli
shorter
length
stay
six
week
later
differ
spirometri
patient
group
health
statu
similar
measur
day
admiss
thu
benefit
steroid
therapi
exacerb
obviou
earli
cours
exacerb
similar
proport
patient
approxim
studi
group
requir
treatment
exacerb
within
week
followup
emphas
high
exacerb
frequenc
patient
niewoehn
colleagu
perform
random
control
trial
either
prednisolon
cours
exacerb
compar
placebo
addit
exacerb
therapi
primari
end
point
first
treatment
failur
includ
death
need
intub
readmiss
intensif
therapi
differ
result
use
treatment
protocol
rate
treatment
failur
higher
placebo
group
day
compar
combin
prednisolon
group
studi
davi
colleagu
fev
improv
faster
prednisolonetr
group
though
differ
week
contrast
niewoehn
colleagu
perform
detail
evalu
steroid
complic
found
consider
evid
hyperglycemia
steroidtr
patient
thu
steroid
use
copd
exacerb
short
cours
week
durat
avoid
risk
complic
acut
exacerb
copd
often
present
increas
sputum
purul
volum
antibiot
tradit
use
firstlin
therapi
exacerb
howev
viral
infect
may
trigger
signific
proport
acut
infect
exacerb
copd
antibiot
use
consequ
secondari
infect
studi
investig
benefit
antibiot
acut
exacerb
demonstr
greater
treatment
success
rate
patient
treat
antibiot
especi
initi
present
symptom
increas
dyspnea
sputum
volum
purul
patient
mild
copd
obtain
less
benefit
antibiot
therapi
random
placebocontrol
studi
investig
valu
antibiot
patient
mild
obstruct
lung
diseas
commun
conclud
antibiot
therapi
acceler
recoveri
reduc
number
relaps
metaanalysi
trial
antibiot
therapi
copd
identifi
nine
studi
signific
durat
conclud
antibiot
therapi
offer
small
signific
benefit
outcom
acut
exacerb
hypoxemia
occur
sever
exacerb
usual
requir
hospit
admiss
caution
alway
taken
provid
supplement
oxygen
patient
copd
particularli
acut
exacerb
respiratori
drive
muscl
strength
impair
lead
signific
increas
carbon
dioxid
tension
rel
modest
oxygen
flow
rate
howev
vast
major
case
administr
supplement
oxygen
increas
arteri
oxygen
tension
suffici
without
clinic
signific
rise
carbon
dioxid
suggest
supplement
oxygen
deliv
initi
flow
rate
lminut
via
nasal
cannula
inspir
oxygen
via
venturi
mask
repeat
blood
ga
analysi
minut
oxygen
therapi
hypercapnia
copd
exacerb
may
manag
initi
use
respiratori
stimul
commonli
use
doxapram
act
central
increas
respiratori
drive
respiratori
muscl
activ
effect
probabl
appreci
hour
main
factor
limit
use
sideeffect
lead
agit
often
toler
patient
studi
clinic
efficaci
doxapram
shortterm
investig
suggest
improv
acidosi
arteri
carbon
dioxid
tension
attain
small
studi
compar
doxapram
noninvas
ventil
nippv
acut
exacerb
copd
suggest
nippv
superior
regard
correct
blood
gase
initi
treatment
phase
increas
pulmonari
arteri
pressur
acut
exacerb
copd
result
rightsid
cardiac
dysfunct
develop
peripher
edema
diuret
therapi
may
thu
necessari
edema
rise
jugular
venou
pressur
introduct
noninvas
posit
pressur
ventil
nippv
use
nasal
face
mask
major
impact
manag
acut
exacerb
enabl
acidosi
correct
earli
stage
studi
shown
nippv
produc
improv
ph
rel
rapidli
hour
institut
ventil
allow
time
convent
therapi
work
oxygen
therapi
bronchodil
steroid
antibiot
thu
revers
progress
respiratori
failur
reduc
mortal
nippv
improv
minut
ventil
reduct
respiratori
rate
transdiaphragmat
activ
thu
nippv
improv
ga
exchang
allow
respiratori
muscl
rest
respiratori
failur
use
nippv
patient
comfort
improv
also
requir
sedat
preserv
speech
swallow
techniqu
appli
gener
ward
though
high
depend
area
prefer
intens
care
unnecessari
patient
cooper
import
applic
nippv
main
advantag
use
nippv
avoid
tracheal
intub
abil
offer
ventilatori
support
patient
respiratori
failur
due
sever
copd
would
consid
unsuit
intub
lower
incid
nosocomi
penumonia
also
report
use
nippv
compar
convent
intub
ventil
follow
number
uncontrol
studi
random
control
trial
shown
benefit
nippv
acut
copd
exacerb
uk
studi
show
use
nippv
exacerb
respiratori
failur
earlier
correct
ph
achiev
togeth
reduct
breathless
initi
day
ventil
compar
control
standard
therapi
group
studi
usa
show
signific
reduct
intub
rate
nippv
group
receiv
convent
therapi
nippv
group
third
studi
show
convincingli
patient
exacerb
respiratori
failur
use
nippv
pressur
support
ventil
reduc
need
intub
mortal
significantli
reduc
convent
treat
group
nippv
group
complic
specif
associ
use
mechan
ventil
also
reduc
differ
mortal
disappear
adjust
intub
suggest
benefit
nippv
due
fewer
patient
requir
intubationthi
also
first
studi
show
hospit
length
stay
reduc
use
nippv
recent
studi
show
nippv
appli
gener
ward
though
patient
sever
acidosi
wors
outcom
studi
treat
patient
ph
rather
prognosi
copd
worsen
number
patient
may
improv
without
nippv
though
seem
major
effect
nippv
earlier
correct
acidosi
thu
avoid
tracheal
intub
associ
complic
studi
shown
nippv
success
implement
case
nippv
less
success
patient
wors
blood
gase
baselin
ventil
underweight
higher
incid
pneumonia
greater
level
neurolog
deterior
complianc
ventil
poor
moretti
colleagu
recent
shown
late
treatment
failur
initi
hour
therapi
nippv
patient
late
failur
like
sever
function
clinic
diseas
complic
time
admiss
identif
patient
potenti
poor
outcom
import
delay
intub
seriou
consequ
patient
nippv
fail
unavail
hospit
invas
ventil
may
requir
presenc
increas
acidosi
chapter
may
consid
patient
ph
fall
decis
ventil
patient
may
difficult
though
improv
mode
invas
ventilatori
support
better
wean
techniqu
outlook
copd
patient
better
patient
suitabl
tracheal
intub
first
present
copd
exacerb
respiratori
failur
treatabl
caus
respiratori
failur
pneumonia
inform
requir
past
histori
qualiti
life
especi
abil
perform
daili
activ
patient
sever
disabl
progress
copd
may
less
suitabl
import
adequ
appropri
therapi
use
patient
document
diseas
progress
patient
wish
close
rel
consid
decis
institut
withhold
lifesupport
therapi
mani
hospit
admiss
relat
exacerb
copd
thu
reduct
admiss
especi
winter
month
frequent
particularli
desir
last
year
number
differ
model
support
discharg
develop
evalu
patient
discharg
earli
appropri
packag
care
organ
includ
domiciliari
visit
made
patient
discharg
train
respiratori
nurs
cotton
colleagu
random
patient
either
discharg
next
day
usual
manag
found
differ
mortal
readmiss
rate
two
group
reduct
hospit
stay
mean
day
day
anoth
larger
studi
skwarska
colleagu
patient
random
either
discharg
day
assess
convent
manag
differ
readmiss
rate
differ
visit
primari
care
physician
health
statu
measur
week
discharg
similar
two
group
author
also
demonstr
signific
cost
save
around
home
support
group
compar
admit
group
howev
consider
need
taken
account
organ
assist
discharg
servic
resourc
releas
nurs
follow
patient
benefit
may
season
copd
admiss
particular
problem
winter
month
work
requir
differ
model
support
discharg
avail
costeffect
program
rel
littl
attent
paid
aspect
prevent
exacerb
patient
copd
respiratori
tract
infect
common
factor
caus
exacerb
influenza
pneumococc
vaccin
recommend
patient
signific
copd
studi
review
outcom
influenza
vaccin
cohort
elderli
patient
chronic
lung
diseas
found
influenza
vaccin
associ
signific
health
benefit
fewer
outpati
visit
fewer
hospit
reduc
mortal
longterm
antibiot
therapi
use
patient
frequent
exacerb
though
littl
evid
effect
recent
report
effect
immunostimulatori
agent
patient
copd
exacerb
reduct
sever
complic
hospit
admiss
activ
treat
group
studi
effect
agent
prevent
copd
exacerb
requir
recent
isold
studi
longterm
inhal
steroid
patient
moder
sever
copd
small
reduct
exacerb
frequenc
demonstr
howev
overal
exacerb
frequenc
rel
low
studi
probabl
due
retrospect
assess
exacerb
anoth
earlier
studi
suggest
sever
exacerb
may
reduc
inhal
steroid
therapi
observ
studi
show
exacerb
increas
follow
withdraw
inhal
steroid
though
studi
placebocontrol
two
recent
studi
also
shown
small
reduct
exacerb
achiev
bronchodil
therapi
though
studi
involv
rel
short
period
therapi
week
mahler
colleagu
found
time
first
exacerb
longer
therapi
longact
betaagonist
salmeterol
though
overal
number
exacerb
studi
rel
small
van
noord
colleagu
similar
studi
suggest
combin
salmeterol
ipratropium
effect
reduct
exacerb
longerterm
studi
effect
bronchodil
copd
exacerb
requir
need
increas
patient
educ
detect
treat
exacerb
earli
natur
histori
chapter
specif
written
treatment
plan
copd
patient
risk
may
use
produc
asthmat
though
approach
requir
formal
test
follow
exacerb
copd
patient
condit
review
attent
given
risk
factor
complianc
therapi
strategi
reduc
exacerb
frequenc
need
urgent
developedw
better
posit
reduc
significantli
morbid
associ
copd
exacerb
improv
healthrel
qualiti
life
patient
disabl
condit
